Corcept Therapeutics
CORT
63.62
-1.36
-2.09%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
63.62
-1.36
-2.09%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 1
■ Upgrades■ Downgrades
- 2 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Wolfe Research moved from Hold to Sell on 2026-07-26.
Analyst consensus 4 analysts
Buy
Avg price target 165.75 +160.5%
Price target rangecurrent 63.62
Low161.00
Avg165.75
High173.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-05 | CCORF | -- | Buy | 161.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-11-04 | Piper Sandler | -- | Buy | 173.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-11-02 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-10-27 | CCORF | -- | Buy | 161.00 |
| 2026-10-27 | Piper Sandler | -- | Buy | 165.00 |
| 2026-10-26 | CCORF | -- | Buy | 161.00 |
| 2026-10-26 | Piper Sandler | -- | Buy | 165.00 |
| 2026-10-19 | Piper Sandler | -- | Buy | 165.00 |
| 2026-10-14 | CCORF | -- | Buy | 161.00 |
| 2026-10-07 | Piper Sandler | -- | Buy | 165.00 |
| 2026-10-01 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-09-18 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-08-21 | Piper Sandler | -- | Buy | 165.00 |
| 2026-08-18 | Truist Financial | -- | Buy | 164.00 |
| 2026-08-13 | CCORF | -- | Buy | 161.00 |
| 2026-07-30 | CCORF | -- | Buy | 161.00 |
| 2026-07-30 | Piper Sandler | -- | Buy | 165.00 |
| 2026-07-30 | H.C. Wainwright | -- | Buy | 165.00 |
| 2026-07-29 | CCORF | -- | Buy | 161.00 |
| 2026-07-29 | Wolfe Research | -- | Sell | 50.00 |
| 2026-07-26 | Wolfe Research | -- | Sell | 50.00 |
| 2026-07-09 | CCORF | -- | Buy | 135.00 |
| 2026-06-02 | H.C. Wainwright | -- | Buy | 95.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-07-26 | Wolfe Research | Hold → Sell | 50.00 |
| 2026-05-13 | UBS | Hold → Buy | 72.00 |
| 2026-03-26 | Wolfe Research | Sell → Hold | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-03 | After close | ±11.96% | -3.31% (in line) |
| 2026/Q2 | 2026-07-29 | After close | ±11.98% | +27.29% (beat) |
| 2026/Q1 | 2026-04-30 | After close | ±8.03% | +10.53% (beat) |
| 2025/Q4 | 2026-02-24 | After close | ±10.55% | -0.71% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±12.65% | +7.81% (in line) |
| 2025/Q2 | 2025-07-31 | After close | ±11.59% | +2.72% (in line) |
| 2025/Q1 | 2025-05-05 | After close | ±12.10% | -4.33% (in line) |
| 2024/Q4 | 2025-02-26 | After close | ±23.17% | -5.55% (in line) |
| 2024/Q3 | 2024-10-30 | After close | ±18.92% | +4.44% (in line) |
| 2024/Q2 | 2024-07-29 | After close | ±15.02% | -1.12% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±13.10% | +4.94% (in line) |
| 2023/Q4 | 2024-02-15 | After close | ±17.81% | -7.15% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Corcept Therapeutics discussion 0 comments